A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE

PHASE4CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 12, 2017

Primary Completion Date

May 28, 2019

Study Completion Date

June 15, 2020

Conditions
Lupus Erythematosus, SystemicLupus ErythematosusFatigue
Interventions
DRUG

RAYOS

FDA approved RAYOS for indication of fatigue in Lupus.

DRUG

Prednisone

FDA approved corticosteroid frequently used for SLE.

Trial Locations (21)

10021

The Hospital for Special Surgery, New York

10032

Columbia University Medical Center, New York

17033

Hershey Medical Center, Hershey

19140

Temple University, Philadelphia

21201

University of Maryland School of Medicine, Baltimore

27599

University of North Carolina at Chapel Hill, Chapel Hill

32610

University of Florida College of Medicine, Gainesville

33136

Miller School of Medicine at the University of Miami, Miami

44109

The MetroHealth System, Cleveland

60611

Northwestern University, Chicago

60612

Rush University Medical Center, Chicago

73104

Oklahoma Medical Research Foundation, Oklahoma City

90048

Cedars-Sinai Medical Center, Los Angeles

90095

The Regents of the University of California, Los Angeles, Los Angeles

92037

The Regents of the University of California, San Diego, San Diego

92868

University of California-Irvine, Orange

94143

University of California-San Francisco, San Francisco

94304

Stanford University, Palo Alto

06519

Yale School of Medicine, New Haven

02114

Massachusetts General Hospital, Boston

01605

UMASS Memorial Medical Center-Memorial Campus, Worcester

All Listed Sponsors
lead

Ampel BioSolutions, LLC

INDUSTRY

NCT03098823 - A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE | Biotech Hunter | Biotech Hunter